ArticleBMC microbiology2026
Intensified upstream processing by a phosphate-regulated, auto-inducible expression system in E. coli W3110 for recombinant Fab production.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEscherichia coli is a microbial expression system widely spread in industrial manufacturing systems for the production of biotherapeutics. Most of these recombinant protein production processes are established in fed-batch operation mode. While many sectors of the chemical industry have implemented intensification strategies, the bio-pharmaceutical sector lacks a profound change towards intensified operations due to a decrease of cellular productivity during extended cultivation periods.
resultsIn this study, intensified bioreactor cultivations of an auto-inducible E. coli strain W3110 as a promising candidate for the production of a recombinant fragment antigen binding (Fab) are demonstrated. The main goal was to investigate the impact of the natural phosphate limitation on the activity of the alkaline phosphatase promoter (phoA) in terms of cell-specific productivity in different processing modes. Following a cell-physiological characterization in fed-batch operation, the transition to intensified upstream processing modes, such as repetitive fed-batch and chemostat was established successfully. A comprehensive understanding of phosphate limitation and precise control of critical parameters, such as growth rate and phosphate-to-substrate uptake enabled the intensified process to match specific product titers and surpass process efficiency (in terms of space-time yield) compared to fed-batch mode.
conclusionsThe auto-inducible phoA promoter in E. coli W3110 enabled stable Fab production under intensified bioprocess operations. These findings highlight the suitability of this expression system for repetitive fed-batch and chemostat operations to support broader adoption of intensified strategies in the bio-pharmaceutical industry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.